Schedule 13G

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, B8liimZGRoKQllm8uSo5hjBkAiW8pWrEK/GQDY9ImnIEADp7qFQ5fP2jKlKsv87g LfxsmiJfvaVE0EHLYlApcA== 0001193125-07-052207.txt : 20070312 0001193125-07-052207.hdr.sgml : 20070312 20070312161617 ACCESSION NUMBER: 0001193125-07-052207 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070312 DATE AS OF CHANGE: 20070312 GROUP MEMBERS: ESSEX WOODLANDS HEALTH VENTURES VI, L.L.C. GROUP MEMBERS: ESSEX WOODLANDS HEALTH VENTURES VI, L.P. GROUP MEMBERS: IMMANUEL THANGARAJ GROUP MEMBERS: JAMES L. CURRIE GROUP MEMBERS: JEFF HIMAWAN GROUP MEMBERS: MARK PACALA GROUP MEMBERS: MARTIN P. SUTTER GROUP MEMBERS: PETRI VAINIO SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ZIOPHARM ONCOLOGY INC CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841475642 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-79364 FILM NUMBER: 07687829 BUSINESS ADDRESS: STREET 1: 1180 AVENUE OF THE AMERICA STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 617-214-0700 MAIL ADDRESS: STREET 1: 1180 AVENUE OF THE AMERICA STREET 2: 19TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ESSEX WOODLANDS HEALTH VENTURES FUND VI L P CENTRAL INDEX KEY: 0001276801 IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 190 SOUTH LASALLE ST STREET 2: SUITE 2800 CITY: CHICAGO STATE: IL ZIP: 60603 BUSINESS PHONE: 312-444-6040 SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Ziopharm Oncology, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

98973P101

(CUSIP Number)

Martin P. Sutter

Essex Woodlands Health Ventures Fund V, L.P.

21 Waterway Avenue, Suite 225

The Woodlands, Texas 77380

(281) 364-1555

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

February 22, 2007

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13G-1(b)

x Rule 13G-1(c)

¨ Rule 13G-1(d)

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G


CUSIP No. 98973P101				Page 2 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Essex Woodlands Health Ventures Fund VI, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		6 SHARED VOTING POWER -0-
		7 SOLE DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		8 SHARED DISPOSITIVE POWER -0-


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON PN


CUSIP No. 98973P101				Page 3 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Essex Woodlands Health Ventures VI, L.P.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		6 SHARED VOTING POWER -0-
		7 SOLE DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		8 SHARED DISPOSITIVE POWER -0-


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON OO


CUSIP No. 98973P101				Page 4 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Essex Woodlands Health Ventures VI, L.L.C.
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION Delaware


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		6 SHARED VOTING POWER -0-
		7 SOLE DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		8 SHARED DISPOSITIVE POWER -0-


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON OO


CUSIP No. 98973P101				Page 5 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON James L. Currie
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN


CUSIP No. 98973P101				Page 6 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Martin P. Sutter
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN


CUSIP No. 98973P101				Page 7 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Immanuel Thangaraj
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN


CUSIP No. 98973P101				Page 8 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Mark Pacala
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN


CUSIP No. 98973P101				Page 9 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Jeff Himawan
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN


CUSIP No. 98973P101				Page 10 of 14 Pages


1		NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Petri Vainio
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ (b) x
3		SEC USE ONLY
4		CITIZENSHIP OR PLACE OF ORGANIZATION United States


NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5 SOLE VOTING POWER -0-
		6 SHARED VOTING POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
		7 SOLE DISPOSITIVE POWER -0-
		8 SHARED DISPOSITIVE POWER 2,296,652 (includes 382,776 shares under immediately exercisable warrants)


9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,296,652 (includes 382,776 shares under immediately exercisable warrants)
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.84%
12	TYPE OF REPORTING PERSON IN

ORIGINAL REPORT ON SCHEDULE 13G

Item 1.

(a)

Name of Issuer:

Ziopharm Oncology, Inc.

(b)

Address of Issuer’s Principal Executive Offices:

1180 Avenue of the Americas, 19^th Floor New York, NY 10036

Item 2.

(a)

Name of Person Filing:

This Schedule 13G is being filed jointly by Essex Woodlands Health Ventures Fund VI, L.P., a Delaware limited partnership (the “Partnership”), Essex Woodlands Health Ventures VI, L.P., a Delaware limited partnership the general partner of the Partnership, (the “GP Partnership”), Essex Woodlands Health Ventures VI, L.L.C., a Delaware limited liability company the general partner of the GP Partnership, James L. Currie, an individual, Martin P. Sutter, an individual, Immanuel Thangaraj, an individual, Petri Vainio, an individual, Mark Pacala, an individual and Jeff Himawan an individual (each a “Manager”, collectively, the “Managers”, and together with the Partnership, GP Partnership and the General Partner, the “Reporting Persons”).

(b)

Address of Principal Business Office:

The address of the principal business of each of the Reporting Persons is 21 Waterway, Suite 225, The Woodlands, Texas 77380.

(c)

Citizenship:

(i) Essex Woodlands Health Ventures Fund VI, L.P. is a Delaware limited partnership; (ii) Essex Woodlands Health Ventures VI, LP is a Delaware limited partnership, (iii) Essex Woodlands Health Ventures VI, L.L.C. is a Delaware limited liability company; (iv) James L. Currie, Martin P. Sutter, Immanuel Thangaraj, Mark L. Pacala, Petri Vainio and Jeff Himawan are all individuals who are citizens of the United States.

(d)

Title of Class of Securities:

Common Stock, par value $.001 per share

(e)

CUSIP Number:

98973P101

Item 3.

If this statement is filed pursuant to §§240.13G-1(b), or 240.13G-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a 8).

(e)

An investment adviser in accordance with 240.13G 1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with 240.13G 1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with 240.13G 1(b)(1)(ii)(G);

(h)

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a 3);

(j)

Group, in accordance with 240.13G 1(b)(1)(ii)(J).



Item 4.	Ownership.

	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

	(a)	Amount Beneficially Owned. As of the date of this filing, each Reporting Person may be deemed to be the beneficial owner of 1,913,876 shares of Common Stock and 382,776 shares under immediately exercisable warrants. The Partnership purchased the Common Stock as part of a private placement on February 22, 2007. The General Partner may be deemed to have voting control and investment discretion over securities owned by the Partnership. The Managers may be deemed to be the beneficial owner of any shares deemed to be beneficially owned by the General Partner. The foregoing should not be construed in and of itself as an admission by the General Partner or the Managers as to beneficial ownership of the shares owned by the Partnership.

	(b)	Percent of Class. 10.84% of the Common Stock (see Item 4(a) above), which percentage was calculated based on shares of Common Stock outstanding, as reported in the Issuer’s prospectus filed with the Commission on February 13, 2007.

	(c)	Number of shares as to which such person has:

		(i)	Sole power to vote or to direct the vote: -0-

		(ii)	Shared power to vote or direct the vote: 2,296,652 (includes 382,776 shares under immediately exercisable warrants)

		(iii)	Sole power to dispose or to direct the disposition of: -0-

		(iv)	Shared power to dispose or to direct the disposition of: 2,296,652 (includes 382,776 shares under immediately exercisable warrants)

Item 5.	Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

Item 6.	Ownership of More than Five Percent on Behalf of Another Person N/A

Item 7.	Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company N/A

Item 8.	Identification and Classification of Members of the Group N/A

Item 9.	Notice of Dissolution of Group N/A

Item 10.	Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: March 9, 2007


ESSEX WOODLANDS HEALTH VENTURES FUND VI, L.P.		INDIVIDUALS:

By:	Essex Woodlands Health Ventures VI, L.P., Its General Partner		/s/ James L. Currie
		Name:	James L. Currie
By:	Essex Woodlands Health Ventures VI, .L.L.C., Its General Partner
			/s/ Martin P. Sutter
By:	/s/ Martin P. Sutter	Name:	Martin P. Sutter
Name:	Martin P. Sutter
Title:	Managing Director

ESSEX WOODLANDS HEALTH VENTURES VI, L.P.			/s/ Immanuel Thangaraj
		Name:	Immanuel Thangaraj
By:	Essex Woodlands Health Ventures VI, .L.L.C., Its General Partner
			/s/ Mark L. Pacala
By:	/s/ Martin P. Sutter	Name:	Mark L. Pacala
Name:	Martin P. Sutter
Title:	Managing Director
			/s/ Jeff Himawan
ESSEX WOODLANDS HEALTH VENTURES VI, L.L.C.		Name:	Jeff Himawan

	/s/ Martin P. Sutter
Name:	Martin P. Sutter
Title:	Managing Director		/s/ Petri Vainio
		Name:	Petri Vainio

Exhibit 1

JOINT FILING AGREEMENT

Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Common Stock of Ziopharm Oncology, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13G-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such statement on Schedule 13G as to any of the undersigned upon such person giving written notice thereof to each of the other persons signature hereto, at the principal office thereof.

This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Date: March 9, 2007


ESSEX WOODLANDS HEALTH VENTURES FUND VI, L.P.			INDIVIDUALS:

By:	Essex Woodlands Health Ventures VI, L.P., Its General Partner		/s/ James L. Currie
		Name:	James L. Currie
By:	Essex Woodlands Health Ventures VI, .L.L.C., Its General Partner
			/s/ Martin P. Sutter
By:	/s/ Martin P. Sutter	Name:	Martin P. Sutter
Name:	Martin P. Sutter
Title:	Managing Director

ESSEX WOODLANDS HEALTH VENTURES VI, L.P.			/s/ Immanuel Thangaraj
		Name:	Immanuel Thangaraj
By:	Essex Woodlands Health Ventures VI, L.L.C., Its General Partner
			/s/ Mark L. Pacala
		Name:	Mark L. Pacala
By:	/s/ Martin P. Sutter
Name:	Martin P. Sutter
Title:	Managing Director
			/s/ Jeff Himawan
		Name:	Jeff Himawan

ESSEX WOODLANDS HEALTH VENTURES VI, L.L.C.

	/s/ Martin P. Sutter		/s/ Petri Vainio
Name:	Martin P. Sutter	Name:	Petri Vainio
Title:	Managing Director

-----END PRIVACY-ENHANCED MESSAGE-----